Contoh Kasus
Contoh Kasus
A. Identitas Pasien
Nama Pasien : Tn. B
Umur : 55 tahun
No. RM : 00-00-46-XX-XX
TB/BB : 178 cm/69 kg
MRS/KRS : 30/05/2019 s/d 08/06/2019
Riwayat Penyakit : Hipertensi, Diabetes Mellitus, TB Paru
Riwayat Obat : Amlodipine, Levemir, Glidiab, Glucobay, Lanzoprazole, Ranitidin,
Harnal (7 bulan lalu), Rifampisin, INH
Diagnosis : DM Hiperglikemia, Anemia, TB Paru
B. SOAP
1. Subjektif
Sejak 1 minggu yang lalu pasien berkeringat dingin, pasien merasa badan gemetar, lemas dan
pusing mbliyur.
2. Objektif
1. Kondisi klinik
Kondisi Tanggal
Klinik 30/06 31/06 01/06 02/06 03/06 04/06 05/06 06/06 07/06 08/06
Lemas + + + + + + + + - -
Pusing + + + + + - - - - -
Perut
- + + - - - - - - -
kembung
Keringat
- - + - - - - - - -
dingin
Polifagi - - + - - - - - - -
Batuk - - + + + - - - - -
2. Tanda – tanda vital (TTV)
Tanggal
TTV 04/0
30/05 31/05 01/06 02/06 03/06 05/06 06/06 07/06 08/06
6
Tekanan 170/ 180/ 140/ 150/ 170/ 190/ 150/ 130/ 140/ 140/
Darah 90 100 90 90 100 100 100 90 90 90
Nadi
100 80 80 80 80 88 80 84 80 80
(80-100 x/min)
RR
20 20 20 20 20 20 18 18 20 20
(16-20 x/min)
Suhu (oC) 37,2 37,4 36,8 36 36,6 37 36,6 36 36 36
3. Parameter Laboratorium
Tanggal
Parameter
30/05 31/05 01/06 03/06 04/06 05/06 07/06
3
WBC (4 – 10 x 10 /UL) 7,3 8,6 9,1 6,7 6,5
RBC (3,5 – 5 x 106/UL) 2,87 2,95 2,99 2,75 3,75
HGB (12 – 16 g/dL) 8,3 8,8 8,6 7,7 10,9
HCT (37 – 54%) 23,8 25,1 25,3 23,2 31,1
MCV (80-100 fl) 83 85,2 84,5 84,2 82,9
MCH (27-34%) 28,9 29,8 28,8 28 29,1
MCHC (32-36%) 34,8 35 34 33,3 35,1
PLT (150 – 400 x 103/UL) 157 214 209 181 175
LED (0 – 8 mm/jam) 95 106 105
GDA (< 200 mg/dL) 321 334 164
GDP (70 – 110 mg/dL ) 235 142
GD 2 JPP (< 80-125 mg/dL) 213
HbA1c (%) 5,3
TG (50 – 200 mg/dL) 135 125
Kolesterol 229
(150 – 200 mg/dL)
HDL-C (35 – 55 mg/dL) 60
LDL-C (65 – 175 mg/dL) 151
Globulin (2,2 – 3,5 mg/dL) 1,7 2,9
Albumin (3,5 – 5) 2,4 2,6
BUN (10 – 24 mg/dL) 27 32 30
Creatinin (0,5 – 1,5 mg/dL) 2,4 2,2 2,1
Na (135 – 145 mmol/L) 128 131,6
K (3,5 – 5 mmol/L) 4,5 4,23
Cl (95 – 108 mmol/L) 100 102
Ca (8,6 – 10,3 mmol/L) 7,5
UA (3,4 – 7 mg/dL) 5,1 5,5
Urinalisa
Protein ++
4. Pemeriksaan Penunjang
Photothorax (01-06-2019):
Kesan : Radang lama paru kanan atas terkesan masih tampak aktif
Tanggal
Nama Obat Dosis
30/05 31/05 01/06 02/06 03/06 04/06 05/06 06/06 07/06 08/06
Infus Kidmin : NaCl 2:1 √ √ √ √ √ STOP
Inj Levofloxacin 500 mg 0-0-1 √ √ √ √ √ √ STOP
Novorapid 3x16 U √ √ √ √ √ STOP
Levemir 0-0-10 U √ √ √ √ √ √ √ √
Micardis 80 mg 1-0-0 √ √ √ √ √ √ √ √ √ √
Inj Lasix 1-0-0 √ STOP √
Rifampicin 600 mg 0-0-1 √ √ √
INH 300 mg 0-0-1 √ √ √
STOP
Mucylin 200 mg 0-0-1 √ √ √
Codein + Salbutamol 0-0-1 √ √ √
Spironolakton 100 mg 1-0-0 √ √
Furosemide 40 mg 1-0-0 √ √ √ √ -
Amlodipin 10 mg 0-0-1 √ √ √ √ √
Glikuidon 30 mg 1-1/2 -0 √ √ √ √ √
Difehidramin syr 3x1C √ √ √ √ √
Bisoprolol 5 mg 1-0-0 √ √ √ √
Diazepam 0-0-1 √ √ √ STOP
Transfusi PRC 2 kolf √
C. ASSESSMENT
Problem Medik Subjektif, Objektif Terapi DRPs
DM Hiperglikemi S: lemas, polifagia 1. Novorapid 3 Terapi insulin adekuat,
+ x16 U Pasien mengalami hiperglikemia dapat dimungkinkan karena
Nefropathy O: edema (30 Mei – 3 adanya penurunan efektivitas obat antidiabetik oral yg dikonsumsi
GDA : 321, 334, Juni) bersamaan dengan obat antituberkulosis (Rifampisin) (Depkes RI,
164 2. Levemir 0-0-10 2005).
GDP : 235, 142 U
GD2JPP : 213 (30 Mei – 7 Penurunan glukosa darah acak sudah tercapai dengan penggunaan
HbA1C : 5,3% Juni) insulin Novorapid sehingga terapi dikembalikan seperti semula,
yaitu dengan obat antidiabetik oral (Glikuidon) dan insulin basal.
BUN : 27; 32; 30 Glikuidon merupakan golongan sulfonilurea yang tepat pada
Cr : 2,4; 2,2; 2,1 pasien DM dengan gangguan fungsi ginjal (Koda-Kimble, 2013).
E. MONITORING TERAPI
Kondisi klinik:
1. Pusing
2. Udem (volum urin)
3. Lemas
4. Efek samping hipoglikemia
Tanda-tanda vital:
1. Penurunan tekanan darah pasien
2. Nadi
Laboratorium:
1. Penurunan glukosa darah
2. Monitoring kadar Hb pasien
3. USG abdomen untuk melihat ukuran batu empedu
4. Monitoring kadar Kalium dan albumin
DAFTAR PUSTAKA
Ahrens, N., Genth, R., Salama, A., 2002, Belated diagnosis in three patients with rifampicin-
induced immune haemolytic anaemia, Case Report, Br J Haematol, 117(2):441-443.
Alsultan etc, 2015, Limited sampling strategy an target Attainment Analysis for Levofloxacin in
Patients with Tuberculosis, Antimicrob Agents Chemother, 00341-15.
Ashley, C and Currie, A., 2004, The Renal Drug Handbook, 3 rd edition, Radcliffe Publishing,
Oxford, New York.
Menzies, D., Alvarez, G.G., and Khan, K., 2014, Canadian Tuberculosis Standards, 7th edition,
Public health Agency of Canada, Canada.
Coyne, 2012, CKD Medscape CME Expert Column Series: Issue 3 — Management of Chronic
Kidney Disease Comorbidities, CME
Dipiro et al, 2008, Pharmacotherapy: A Pathophysiologic Approach, 7th ed., Mc Graw Hill, New
York
JNC 7, 2003, Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National
Institute of Health.
JNC 8, 2014, 2013, Evidence-BasedGuideline for theManagement of HighBlood Pressure
inAdults, Clinical Review and Education, JAMA. 2014;311(5):507-520.
doi:10.1001/jama.2013.284427
Kidney International Supplements, 2012, KDIGO Clinical Practice Guideline for Anemia in
Chronic Kidney Disease, 2, 288–291
Koda-Kimble, 2009, Applied Therapeutics: The Clinical Use Of Drugs, 9th Edition, Lippincott
Williams & Wilkins
Lacy, et al., 2013, Drug Information Handbook., 21st edition, Lexicomp, United State.
NCGC, 2011, Anemia Management in Chronic Kidney Disease, National Clinical Guideline
Centre, London
Piso, R.J., Kriz, K., and Desax, M.J., 2011, Severe Isoniazid Related Sideroblastic Anemia, Case
Report, Hematol Rep, 3(1); e2 doi 10.4081/hr.2011.e2
Watschinger, et al, .2013, The MAINTAIN study--managing hemoglobin variability with
darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin,
Feb;125(3-4):71-82. doi: 10.1007/s00508-012-0311-1. Epub 2013 Jan 9.
www.medscape.com